VRXA — Veraxa Biotech Holding AG stock price, charts and financials

QT—Veraxa Biotech Holding AG

Veraxa Biotech Holding AG (NASDAQ: VRXA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
1.80
-0.03-1.64%
OverviewShort InterestFilings
VRXAVeraxa Biotech Holding AG·NASDAQ
1.80-1.64%
TA
Loading chart...
Screen all →
OCUL+2.26%$8.59MESO+2.28%$14.80AUPH+2.47%$14.93TYRA+1.53%$32.53URGN+3.45%$39.92IOVA+0.93%$4.36STOK+7.14%$31.67TSHA+7.27%$6.20
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand141.41MPerf Week-9.09%
Market Cap254.53MForward P/E-EPS next Y-Insider Trans-Shs Float12.61MPerf Month-17.81%
Enterprise Value-PEG-EPS next Q-Inst Own-Short Float0.17%Perf Quarter-
Income-P/S-EPS this Y-Inst Trans-Short Ratio0.45Perf Half Y-
Sales-P/B-EPS next Y-ROA-Short Interest240.55KPerf YTD-87.14%
Book/sh-P/C-EPS next 5Y-ROE-52W High27.36 -93.42%Perf Year-
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-52W Low1.70 5.88%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin-Volatility6.37% 12.93%Perf 5Y-
Dividend TTM-EV/Sales-EPS Y/Y TTM-Oper. Margin-ATR (14)0.64Perf 10Y-
Dividend Ex-Date-Quick Ratio-Sales Y/Y TTM-Profit Margin-RSI (14)35.60Recom-
Dividend Gr. 3/5Y-Current Ratio-EPS Q/Q-SMA20-12.75%Beta4.87Target Price-
Payout-Debt/Eq-Sales Q/Q-SMA50-62.77%Rel Volume0.21Prev Close1.83
Employees8LT Debt/Eq-Earnings-SMA200-62.77%Avg Volume701.98KPrice1.80
IPO DateJun 09, 2026Option/ShortNo / YesEPS/Sales Surpr.-Net Debt/EBITDA-Volume149,993Change-1.64%
Latest News
Jul-31-26
Jul-31-2605:17PM
Veraxa Biotech Files Prospectus Related To The Resale Of Up To 25M Ordinary Shares By The Selling ShareholderBenzinga
Jul-29-26
Jul-29-2607:00AM
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidatesglobenewswire.com
Jul-27-26
Jul-27-2607:07AM
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy DiscoveryBenzinga
07:00AM
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAbglobenewswire.com
Jul-24-26
Jul-24-2604:05PM
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growthglobenewswire.com
Jul-23-26
Jul-23-2607:00AM
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolioglobenewswire.com
Jul-20-26
Jul-20-2607:09AM
VERAXA Gets German Regulatory Feedback On Cancer Therapy PlanBenzinga
07:00AM
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Planglobenewswire.com
Jul-13-26
Jul-13-2607:08AM
VERAXA Biotech Partners With AI-Driven Computational R&D Partner Ardigen To Support Its Growing BiTAC Pipeline Of T Cell Engagers And Antibody Drug ConjugatesBenzinga
07:00AM
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipelineglobenewswire.com
Jul-10-26
Jul-10-2604:05PM
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeisterglobenewswire.com
Jul-07-26
Jul-07-2601:05PM
12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga
Jul-06-26
Jul-06-2607:00AM
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelinesglobenewswire.com
Jul-02-26
Jul-02-2607:00AM
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Programglobenewswire.com
Jun-24-26
Jun-24-2601:05PM
12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga
Company

Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.